Viracta Therapeutics (FRA:RYI) EBIT : €-36.75 Mil (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Viracta Therapeutics EBIT?

Viracta Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was €-8.90 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was €-36.75 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Viracta Therapeutics's annualized ROC % for the quarter that ended in Sep. 2024 was -221.86%. Viracta Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -24,456.36%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Viracta Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -1,003.63%.

Viracta Therapeutics EBIT Historical Data

The historical data trend for Viracta Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viracta Therapeutics EBIT Chart

Viracta Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT

-15.45

-101.13

-45.90

-43.42

Viracta Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT	Get a 7-Day Free Trial														-10.91	-11.75	-7.62	-8.49	-8.90

Competitive Comparison of Viracta Therapeutics's EBIT

For the Biotechnology subindustry, Viracta Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viracta Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viracta Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Viracta Therapeutics's EV-to-EBIT falls into.

Viracta Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-36.75 Mil.

Viracta Therapeutics (FRA:RYI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Viracta Therapeutics's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	-36.708 * ( 1 - 0% )	/	( (17.715	+	15.376)	/ 2 )
=	-36.708	/	16.5455
=	-221.86 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	29.098	-	9.134	-	( 27.875	-	max(0, 26.617	-	28.866	+	27.875	))
=	17.715

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	19.784	-	10.509	-	( 19.04	-	max(0, 25.746	-	19.645	+	19.04	))
=	15.376

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Viracta Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Sep. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-35.584	/	( ( (0.191 + max(-8.143, 0))	+	(0.1 + max(-9.904, 0)) )	/	2 )
=	-35.584	/	( ( 0.191	+	0.1 )	/	2 )
=	-35.584	/	0.1455
=	-24,456.36 %

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.991)	-	(9.134	+	0	+	0)
=	-8.143

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.605)	-	(10.509	+	0	+	-3.5527136788005E-15)
=	-9.904

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Viracta Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2024 )
	=	-36.753	/	3.662
	=	-1,003.63 %

Viracta Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of Viracta Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Viracta Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (FRA:RYI) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

VIRX:USA RYIS:Germany

Address

2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007

Website

https://www.viracta.com

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.